Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2009

01-05-2009 | Commentary

A role for islet neogenesis in curing diabetes

Authors: G. L. Pittenger, D. Taylor-Fishwick, A. I. Vinik

Published in: Diabetologia | Issue 5/2009

Login to get access

Excerpt

Endogenous insulin deficiency is the tie that binds all forms of diabetes. Definitive treatment or cure of type 1 and type 2 diabetes cannot occur without a durable reversal of relative or absolute endogenous insulin deficiency. Current efforts to restore physiological insulin secretion include (1) islet or pancreas transplant; (2) exogenous cell therapies, including differentiation of bone marrow cells and embryonic stem cells (ESCs); and (3) islet regeneration from endogenous pancreatic cells. Although they would represent advances, islet or beta cell transplant [1, 2], the artificial pancreas [3, 4], gene therapy [5], and even stem cell therapy [6, 7] cannot be considered restorative approaches unless the results are durable and have an acceptable safety profile. …
Literature
1.
Hogan A, Pileggi A, Ricordi C (2008) Transplantation: current developments and future directions; the future of clinical islet transplantation as a cure for diabetes. Front Biosci 13:1192–1205PubMedCrossRef
2.
Ricordi C, Edlund H (2008) Toward a renewable source of pancreatic beta-cells. Nat Biotechnol 26:397–398PubMedCrossRef
3.
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934–939PubMedCrossRef
4.
Weinzimer SA, Tamborlane WV (2008) Sensor-augmented pump therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 15:118–122PubMed
5.
Xu X, D’Hoker J, Stange G et al (2008) Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132:197–207PubMedCrossRef
6.
Chen C, Zhang Y, Sheng X, Huang C, Zang YQ (2008) Differentiation of embryonic stem cells towards pancreatic progenitor cells and their transplantation into streptozotocin-induced diabetic mice. Cell Biol Int 32:456–461PubMedCrossRef
7.
Liu M, Han ZC (2008) Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. J Cell Mol Med 12:1155–1168PubMedCrossRef
8.
Fiorina P, Shapiro AM, Ricordi C, Secchi A (2008) The clinical impact of islet transplantation. Am J Transplant 8:1990–1997PubMedCrossRef
9.
Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R (2001) Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292:1389–1394PubMedCrossRef
10.
Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M (2001) Insulin production by human embryonic stem cells. Diabetes 50:1691–1697PubMedCrossRef
11.
Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F (2000) Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 49:157–162PubMedCrossRef
12.
D’Amour KA, Bang AG, Eliazer S et al (2006) Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24:1392–1401PubMedCrossRef
13.
Kroon E, Martinson LA, Kadoya K et al (2008) Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26:443–452PubMedCrossRef
14.
Rosenberg L, Duguid WP, Brown RA, Vinik AI (1988) Induction of islet cell proliferation will reverse diabetes in the Syrian golden hamster. Diabetes 37:334–341PubMedCrossRef
15.
Inada A, Nienaber C, Katsuta H et al (2008) Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci USA 105:19915–19919PubMedCrossRef
16.
Pittenger GL, Taylor-Fishwick DA, Johns RH, Burcus N, Kosuri S, Vinik AI (2007) Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs. Pancreas 34:103–111PubMedCrossRef
17.
Rafaeloff R, Pittenger GL, Barlow SW et al (1997) Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J Clin Invest 99:2100–2109PubMedCrossRef
18.
Hanley SC, Pilotte A, Massie B, Rosenberg L (2008) Cellular origins of adult human islet in vitro dedifferentiation. Lab Invest 88:761–772PubMedCrossRef
19.
Fleming A, Rosenberg L (2007) Prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein. J Diabetes Sci Tech 1:231–244
20.
Rosenberg L, Lipsett M, Yoon JW et al (2004) A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. Ann Surg 240:875–884PubMedCrossRef
21.
Fleming A (2008) What will it take to get therapies approved for type 1 diabetes? Ann N Y Acad Sci 1150:25–31PubMedCrossRef
22.
Borelli MI, Stoppiglia LF, Rezende LF et al (2005) INGAP-related pentadecapeptide: its modulatory effect upon insulin secretion. Regul Pept 131:97–102PubMedCrossRef
23.
Taylor-Fishwick DA, Bowman A, Hamblet N, Bernard P, Harlan DM, Vinik AI (2006) Islet neogenesis associated protein transgenic mice are resistant to hyperglycemia induced by streptozotocin. J Endocrinol 190:729–737PubMedCrossRef
24.
Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. J Clin Endocrinol Metab 90:3401–3409PubMedCrossRef
25.
Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B (2001) Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562–1570PubMedCrossRef
26.
Suarez-Pinzon WL, Lakey JR, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 17:631–640PubMedCrossRef
27.
Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41–46PubMedCrossRef
28.
Jamal AM, Lipsett M, Sladek R, Laganiere S, Hanley S, Rosenberg L (2005) Morphogenetic plasticity of adult human pancreatic islets of Langerhans. Cell Death Differ 12:702–712PubMedCrossRef
29.
Bonner-Weir S, Taneja M, Weir GC et al (2000) In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 97:7999–8004PubMedCrossRef
30.
Yatoh S, Dodge R, Akashi T et al (2007) Differentiation of affinity-purified human pancreatic duct cells to beta-cells. Diabetes 56:1802–1809PubMedCrossRef
31.
Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA (2008) In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455:627–632PubMedCrossRef
32.
Rosenberg L, Vinik AI (1989) Induction of endocrine cell differentiation: a new approach to management of diabetes. J Lab Clin Med 114:75–83PubMed
Metadata
Title
A role for islet neogenesis in curing diabetes
Authors
G. L. Pittenger
D. Taylor-Fishwick
A. I. Vinik
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1322-y

Other articles of this Issue 5/2009

Diabetologia 5/2009 Go to the issue

Article

Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cyclic AMP in mice

Article

Sex-related psychological effects on metabolic control in type 2 diabetes mellitus

Review

Regulation of insulin secretion: a matter of phase control and amplitude modulation

Article

Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion

Article

Prevention of neural tube defects by loss of function of inducible nitric oxide synthase in fetuses of a mouse model of streptozotocin-induced diabetes

Short Communication

Potential reno-protective effects of a gluten-free diet in type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits